(Q59267779)
Statements
Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis (English)
Gavin Giovannoni
Florence Casset-Semanaz
Amer Jaber
John King
Luanne Metz
James Simsarian
Bettina Stubinski